Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 147

1.

Target-mediated disposition population pharmacokinetics model of erythropoietin in premature neonates following multiple intravenous and subcutaneous dosing regimens.

D'Cunha R, Schmidt R, Widness JA, Mock DM, Yan X, Cress GA, Kuruvilla D, Veng-Pedersen P, An G.

Eur J Pharm Sci. 2019 Oct 1;138:105013. doi: 10.1016/j.ejps.2019.105013. Epub 2019 Jul 21.

PMID:
31340188
2.

Toxicokinetics of Chiral PCB 136 and Its Hydroxylated Metabolites in Mice with a Liver-Specific Deletion of Cytochrome P450 Reductase.

Li X, Wu X, Kelly KM, Veng-Pedersen P, Lehmler HJ.

Chem Res Toxicol. 2019 Apr 15;32(4):727-736. doi: 10.1021/acs.chemrestox.8b00389. Epub 2019 Feb 20.

PMID:
30729780
3.

A Mechanism-Based Population Pharmacokinetics Model of Erythropoietin in Premature Infants and Healthy Adults Following Multiple Intravenous Doses.

D'Cunha R, Widness JA, Yan X, Schmidt RL, Veng-Pedersen P, An G.

J Clin Pharmacol. 2019 Jun;59(6):835-846. doi: 10.1002/jcph.1368. Epub 2019 Jan 7.

PMID:
30618050
4.

Overlooked Issues on Pharmacokinetics Data Interpretation of Protein Drugs-a Case Example of Erythropoietin.

An G, Schmidt RL, Mock DM, Veng-Pedersen P, Widness JA.

AAPS J. 2018 Nov 26;21(1):6. doi: 10.1208/s12248-018-0269-7. No abstract available.

PMID:
30478521
5.

Development, validation, and potential applications of biotinylated red blood cells for posttransfusion kinetics and other physiological studies: evidenced-based analysis and recommendations.

Mock DM, Nalbant D, Kyosseva SV, Schmidt RL, An G, Matthews NI, Vlaar APJ, van Bruggen R, de Korte D, Strauss RG, Cancelas JA, Franco RS, Veng-Pedersen P, Widness JA.

Transfusion. 2018 Aug;58(8):2068-2081. doi: 10.1111/trf.14647. Epub 2018 May 16. Review.

6.

Population Pharmacokinetics of Darbepoetin in Infants Following Single Intravenous and Subcutaneous Dosing.

An G, Ohls RK, Christensen RD, Widness JA, Mock DM, Veng-Pedersen P.

J Pharm Sci. 2017 Jun;106(6):1644-1649. doi: 10.1016/j.xphs.2017.02.001. Epub 2017 Feb 9.

7.

Estimation of adult and neonatal RBC lifespans in anemic neonates using RBCs labeled at several discrete biotin densities.

Kuruvilla DJ, Widness JA, Nalbant D, Schmidt RL, Mock DM, An G, Veng-Pedersen P.

Pediatr Res. 2017 Jun;81(6):905-910. doi: 10.1038/pr.2017.14. Epub 2017 Jan 18.

8.

A Novel Physiology-Based Mathematical Model to Estimate Red Blood Cell Lifespan in Different Human Age Groups.

An G, Widness JA, Mock DM, Veng-Pedersen P.

AAPS J. 2016 Sep;18(5):1182-1191. doi: 10.1208/s12248-016-9923-0. Epub 2016 May 23.

9.

Models for the red blood cell lifespan.

Shrestha RP, Horowitz J, Hollot CV, Germain MJ, Widness JA, Mock DM, Veng-Pedersen P, Chait Y.

J Pharmacokinet Pharmacodyn. 2016 Jun;43(3):259-74. doi: 10.1007/s10928-016-9470-4. Epub 2016 Apr 2.

10.

A Mass Balance-Based Semiparametric Approach to Evaluate Neonatal Erythropoiesis.

Kuruvilla DJ, Widness JA, Nalbant D, Schmidt RL, Mock DM, Veng-Pedersen P.

AAPS J. 2016 Jan;18(1):187-95. doi: 10.1208/s12248-015-9831-8. Epub 2015 Oct 26.

11.

Autologous Infant and Allogeneic Adult Red Cells Demonstrate Similar Concurrent Post-Transfusion Survival in Very Low Birth Weight Neonates.

Widness JA, Kuruvilla DJ, Mock DM, Matthews NI, Nalbant D, Cress GA, Schmidt RL, Strauss RG, Zimmerman MB, Veng-Pedersen P.

J Pediatr. 2015 Nov;167(5):1001-6. doi: 10.1016/j.jpeds.2015.08.028. Epub 2015 Sep 9.

12.

A Method to Evaluate Fetal Erythropoiesis from Postnatal Survival of Fetal RBCs.

Kuruvilla DJ, Widness JA, Nalbant D, Schmidt RL, Mock DM, Veng-Pedersen P.

AAPS J. 2015 Sep;17(5):1246-54. doi: 10.1208/s12248-015-9784-y. Epub 2015 May 28.

13.

Mathematical model of platelet turnover in thrombocytopenic and nonthrombocytopenic preterm neonates.

Kulshrestha M, Sola-Visner M, Widness JA, Veng-Pedersen P, Mager DE.

Am J Physiol Heart Circ Physiol. 2015 Jan 1;308(1):H68-73. doi: 10.1152/ajpheart.00528.2013. Epub 2014 Oct 31.

14.

Measurement of posttransfusion red cell survival with the biotin label.

Mock DM, Widness JA, Veng-Pedersen P, Strauss RG, Cancelas JA, Cohen RM, Lindsell CJ, Franco RS.

Transfus Med Rev. 2014 Jul;28(3):114-25. doi: 10.1016/j.tmrv.2014.03.003. Epub 2014 Apr 5. Review.

15.

Mean remaining life span: a new clinically relevant parameter to assess the quality of transfused red blood cells.

Kuruvilla DJ, Nalbant D, Widness JA, Veng-Pedersen P.

Transfusion. 2014 Oct;54(10 Pt 2):2724-9. doi: 10.1111/trf.12562. Epub 2014 Feb 24.

16.

Expansion of the neonatal platelet mass is achieved via an extension of platelet lifespan.

Liu ZJ, Hoffmeister KM, Hu Z, Mager DE, Ait-Oudhia S, Debrincat MA, Pleines I, Josefsson EC, Kile BT, Italiano J Jr, Ramsey H, Grozovsky R, Veng-Pedersen P, Chavda C, Sola-Visner M.

Blood. 2014 May 29;123(22):3381-9. doi: 10.1182/blood-2013-06-508200. Epub 2014 Mar 5.

17.

Pharmacodynamically optimized erythropoietin treatment combined with phlebotomy reduction predicted to eliminate blood transfusions in selected preterm infants.

Rosebraugh MR, Widness JA, Nalbant D, Cress G, Veng-Pedersen P.

Pediatr Res. 2014 Feb;75(2):336-42. doi: 10.1038/pr.2013.213. Epub 2013 Nov 11.

18.

Population pharmacodynamic analysis of erythropoiesis in preterm infants for determining the anemia treatment potential of erythropoietin.

Saleh MI, Nalbant D, Widness JA, Veng-Pedersen P.

Am J Physiol Regul Integr Comp Physiol. 2013 May 1;304(9):R772-81. doi: 10.1152/ajpregu.00173.2012. Epub 2013 Mar 13.

19.

A mathematical modeling approach to quantify the role of phlebotomy losses and need for transfusions in neonatal anemia.

Rosebraugh MR, Widness JA, Nalbant D, Veng-Pedersen P.

Transfusion. 2013 Jun;53(6):1353-60. doi: 10.1111/j.1537-2995.2012.03908.x. Epub 2012 Oct 4.

20.

2,2',3,5',6-Pentachlorobiphenyl (PCB 95) and its hydroxylated metabolites are enantiomerically enriched in female mice.

Kania-Korwel I, Barnhart CD, Stamou M, Truong KM, El-Komy MH, Lein PJ, Veng-Pedersen P, Lehmler HJ.

Environ Sci Technol. 2012 Oct 16;46(20):11393-401. doi: 10.1021/es302810t. Epub 2012 Sep 28.

21.

Multidose optimization simulation of erythropoietin treatment in preterm infants.

Rosebraugh MR, Widness JA, Veng-Pedersen P.

Pediatr Res. 2012 Apr;71(4 Pt 1):332-7. doi: 10.1038/pr.2011.75. Epub 2012 Feb 15.

22.

Comparison of red blood cell survival in sheep determined using red blood cells labeled with either biotin at multiple densities or [14C]cyanate: validation of a model to study human physiology and disease.

Mock DM, Matthews NI, Zhu S, Strauss RG, Schmidt RL, Zimmerman MB, Nalbant D, Freise KJ, Saleh M, Veng-Pedersen P, Widness JA.

Transfusion. 2012 May;52(5):963-73. doi: 10.1111/j.1537-2995.2011.03512.x. Epub 2012 Jan 9.

23.

A Bayesian population analysis of the development of type 2 diabetes in the offspring of diabetic parents.

Lin CW, Warram JH, Veng-Pedersen P.

J Pharmacokinet Pharmacodyn. 2011 Oct;38(5):563-79. doi: 10.1007/s10928-011-9208-2. Epub 2011 Aug 11.

PMID:
21833670
24.

Differential pharmacokinetic analysis of in vivo erythropoietin receptor interaction with erythropoietin and continuous erythropoietin receptor activator in sheep.

El-Komy MH, Schmidt RL, Widness JA, Veng-Pedersen P.

Biopharm Drug Dispos. 2011 Jul;32(5):276-88. doi: 10.1002/bdd.757. Epub 2011 Jun 15.

25.

Receptor-based dosing optimization of erythropoietin in juvenile sheep after phlebotomy.

Rosebraugh M, Widness JA, Veng-Pedersen P.

Drug Metab Dispos. 2011 Jul;39(7):1214-20. doi: 10.1124/dmd.110.036855. Epub 2011 Apr 1.

26.

Pharmacodynamic analysis of stress erythropoiesis: change in erythropoietin receptor pool size following double phlebotomies in sheep.

Saleh MI, Widness JA, Veng-Pedersen P.

Biopharm Drug Dispos. 2011 Apr;32(3):131-9. doi: 10.1002/bdd.743. Epub 2011 Jan 10.

27.

Pharmacokinetic analysis of continuous erythropoietin receptor activator disposition in adult sheep using a target-mediated, physiologic recirculation model and a tracer interaction methodology.

El-Komy MH, Widness JA, Veng-Pedersen P.

Drug Metab Dispos. 2011 Apr;39(4):603-9. doi: 10.1124/dmd.110.036236. Epub 2011 Jan 5. Erratum in: Drug Metab Dispos. 2012 Jul;40(7):1450.

28.

Correction for effect of cold storage on immature platelet fraction.

Osei-Bimpong A, Saleh M, Sola-Visner M, Widness J, Veng-Pedersen P.

J Clin Lab Anal. 2010;24(6):431-3. doi: 10.1002/jcla.20426.

29.

Population analysis of ethnicity and first-phase insulin release.

Xie L, Hoffman RP, Veng-Pedersen P.

Diabetes Res Clin Pract. 2010 Sep;89(3):243-9. doi: 10.1016/j.diabres.2010.04.025. Epub 2010 May 31.

30.

Red blood cell (RBC) volume can be independently determined in vivo in the sheep using ovine RBCs labeled at different densities of biotin.

Mock DM, Matthews NI, Zhu S, Burmeister LF, Zimmerman MB, Strauss RG, Schmidt RL, Nalbant D, Freise KJ, Veng-Pedersen P, Widness JA.

Transfusion. 2010 Dec;50(12):2553-64. doi: 10.1111/j.1537-2995.2010.02744.x.

31.

Clearance of polychlorinated biphenyl atropisomers is enantioselective in female C57Bl/6 mice.

Kania-Korwel I, El-Komy MH, Veng-Pedersen P, Lehmler HJ.

Environ Sci Technol. 2010 Apr 15;44(8):2828-35. doi: 10.1021/es901781p.

32.

Evidence of receptor-mediated elimination of erythropoietin by analysis of erythropoietin receptor mRNA expression in bone marrow and erythropoietin clearance during anemia.

Nalbant D, Saleh M, Goldman FD, Widness JA, Veng-Pedersen P.

J Pharmacol Exp Ther. 2010 May;333(2):528-32. doi: 10.1124/jpet.109.163568. Epub 2010 Jan 26.

33.

Erythropoietic response to endogenous erythropoietin in premature very low birth weight infants.

Freise KJ, Widness JA, Veng-Pedersen P.

J Pharmacol Exp Ther. 2010 Jan;332(1):229-37. doi: 10.1124/jpet.109.159905. Epub 2009 Oct 6.

34.

Analysis of PK/PD risk factors for development of type 2 diabetes in high risk population using Bayesian analysis of glucose-insulin kinetics.

Lin CW, Veng-Pedersen P.

J Pharmacokinet Pharmacodyn. 2009 Oct;36(5):421-41. doi: 10.1007/s10928-009-9130-z. Epub 2009 Sep 16.

PMID:
19756980
35.

Erythropoietin pharmacokinetic/pharmacodynamic analysis suggests higher doses in treating neonatal anemia.

Neelakantan S, Widness JA, Schmidt RL, Veng-Pedersen P.

Pediatr Int. 2009 Feb;51(1):25-32. doi: 10.1111/j.1442-200X.2008.02648.x.

36.

Noncompartmental pharmacokinetics analysis of glucose-stimulated insulin response in African-American and Caucasian youths.

Xie L, Hoffman RP, Veng-Pedersen P.

Biopharm Drug Dispos. 2009 Apr;30(3):117-25. doi: 10.1002/bdd.652.

PMID:
19288584
37.

Pharmacodynamic modeling of the effect of changes in the environment on cellular lifespan and cellular response.

Freise KJ, Schmidt RL, Widness JA, Veng-Pedersen P.

J Pharmacokinet Pharmacodyn. 2008 Oct;35(5):527-52. doi: 10.1007/s10928-008-9100-x. Epub 2008 Oct 21.

38.

Pharmacokinetic differentiation of drug candidates using system analysis and physiological-based modelling. Comparison of C.E.R.A. and erythropoietin.

Veng-Pedersen P, Freise KJ, Schmidt RL, Widness JA.

J Pharm Pharmacol. 2008 Oct;60(10):1321-34. doi: 10.1211/jpp/60.10.0008.

39.

Modeling time variant distributions of cellular lifespans: increases in circulating reticulocyte lifespans following double phlebotomies in sheep.

Freise KJ, Widness JA, Schmidt RL, Veng-Pedersen P.

J Pharmacokinet Pharmacodyn. 2008 Jun;35(3):285-323. doi: 10.1007/s10928-008-9089-1. Epub 2008 Jun 14.

40.

The effect of anticoagulant, storage temperature and dilution on cord blood hematology parameters over time.

Freise KJ, Schmidt RL, Gingerich EL, Veng-Pedersen P, Widness JA.

Int J Lab Hematol. 2009 Oct;31(5):496-504. doi: 10.1111/j.1751-553X.2008.01066.x. Epub 2008 Apr 14.

41.

Pharmacodynamic analysis of time-variant cellular disposition: reticulocyte disposition changes in phlebotomized sheep.

Freise KJ, Widness JA, Schmidt RL, Veng-Pedersen P.

J Pharmacokinet Pharmacodyn. 2007 Aug;34(4):519-47. Epub 2007 May 22.

42.

Increased erythropoietin elimination in fetal sheep following chronic phlebotomy.

Freise KJ, Widness JA, Segar JL, Schmidt RL, Veng-Pedersen P.

Pharm Res. 2007 Sep;24(9):1653-9. Epub 2007 Apr 25.

43.

Change in erythropoietin pharmacokinetics following hematopoietic transplantation.

Widness JA, Schmidt RL, Hohl RJ, Goldman FD, Al-Huniti NH, Freise KJ, Veng-Pedersen P.

Clin Pharmacol Ther. 2007 Jun;81(6):873-9. Epub 2007 Apr 11.

44.

Individualized pharmacokinetic risk assessment for development of diabetes in high risk population.

Gupta N, Al-Huniti NH, Veng-Pedersen P.

Diabetes Res Clin Pract. 2007 Oct;78(1):93-101. Epub 2007 Mar 19.

45.

Urinary excretion of darbepoetin after intravenous vs subcutaneous administration to preterm neonates.

Warwood TL, Ohls RK, Lambert DK, Leve EA, Veng-Pedersen P, Christensen RD.

J Perinatol. 2006 Oct;26(10):636-9. Epub 2006 Aug 24.

PMID:
16929342
46.

A 'bottom-up' approach for endo-PK/PD analysis.

Neelakantan S, Widness JA, Schmidt RL, Veng-Pedersen P.

Biopharm Drug Dispos. 2006 Oct;27(7):313-27.

48.

Intravenous administration of darbepoetin to NICU patients.

Warwood TL, Ohls RK, Lambert DK, Jones C, Scoffield SH, Gupta N, Veng-Pedersen P, Christensen RD.

J Perinatol. 2006 May;26(5):296-300.

PMID:
16554846
49.

Bronchoscopic assessment of airway retention time of aerosolized xylitol.

Durairaj L, Neelakantan S, Launspach J, Watt JL, Allaman MM, Kearney WR, Veng-Pedersen P, Zabner J.

Respir Res. 2006 Feb 16;7:27.

50.

Pharmacodynamic analysis of changes in reticulocyte subtype distribution in phlebotomy-induced stress erythropoiesis.

Al-Huniti NH, Widness JA, Schmidt RL, Veng-Pedersen P.

J Pharmacokinet Pharmacodyn. 2005 Aug;32(3-4):359-76.

PMID:
16284920

Supplemental Content

Loading ...
Support Center